{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:32:23Z","timestamp":1758709943148},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2016,8,5]],"date-time":"2016-08-05T00:00:00Z","timestamp":1470355200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s11883-016-0608-z","type":"journal-article","created":{"date-parts":[[2016,8,4]],"date-time":"2016-08-04T22:14:59Z","timestamp":1470348899000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Contemporary Approach to Pulmonary Arterial Hypertension"],"prefix":"10.1007","volume":"18","author":[{"given":"Udhay","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn M.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,5]]},"reference":[{"issue":"1","key":"608_CR1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","volume":"115","author":"Y-C Lai","year":"2014","unstructured":"Lai Y-C, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115\u201330.","journal-title":"Circ Res"},{"issue":"2","key":"608_CR2","doi-asserted-by":"crossref","first-page":"79","DOI":"10.21693\/1933-088X-14.2.79","volume":"14","author":"B Houston","year":"2015","unstructured":"Houston B, Hsu S, Tampakakis E, Tedford R. The right ventricle: a not-so-innocent bystander in pulmonary hypertension due to left heart disease. Advances in Pulmonary Hypertension. 2015;14(2):79\u201387.","journal-title":"Advances in Pulmonary Hypertension"},{"issue":"1","key":"608_CR3","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1378\/chest.119.1.256","volume":"119","author":"S Solway","year":"2001","unstructured":"Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest. 2001;119(1):256\u201370.","journal-title":"Chest"},{"issue":"2","key":"608_CR4","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1378\/chest.108.2.452","volume":"108","author":"L Cahalin","year":"1995","unstructured":"Cahalin L, Pappagianopoulos P, Prevost S, Wain J, Ginns L. The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease. Chest. 1995;108(2):452\u20139.","journal-title":"Chest"},{"issue":"2 Pt 1","key":"608_CR5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/ajrccm.161.2.9906015","volume":"161","author":"S Miyamoto","year":"2000","unstructured":"Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2 Pt 1):487\u201392.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"608_CR6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","volume":"122","author":"M Humbert","year":"2010","unstructured":"Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122(2):156\u201363.","journal-title":"Circulation"},{"issue":"3","key":"608_CR7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1183\/09031936.00092311","volume":"39","author":"N Nickel","year":"2012","unstructured":"Nickel N, Golpon H, Greer M, Knudsen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589\u201396.","journal-title":"Eur Respir J"},{"issue":"2","key":"608_CR8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164\u201372.","journal-title":"Circulation"},{"issue":"12","key":"608_CR9","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","volume":"346","author":"LJ Rubin","year":"2002","unstructured":"Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896\u2013903.","journal-title":"N Engl J Med"},{"issue":"5","key":"608_CR10","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","volume":"334","author":"RJ Barst","year":"1996","unstructured":"Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296\u2013301.","journal-title":"N Engl J Med"},{"issue":"20","key":"608_CR11","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","volume":"353","author":"N Galie","year":"2005","unstructured":"Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148\u201357.","journal-title":"N Engl J Med"},{"issue":"23","key":"608_CR12","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","volume":"117","author":"N Galie","year":"2008","unstructured":"Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010\u20139.","journal-title":"Circulation"},{"issue":"22","key":"608_CR13","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1161\/CIRCULATIONAHA.108.839274","volume":"119","author":"N Galie","year":"2009","unstructured":"Galie N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119(22):2894\u2013903.","journal-title":"Circulation"},{"issue":"6","key":"608_CR14","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","volume":"165","author":"G Simonneau","year":"2002","unstructured":"Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800\u20134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"608_CR15","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ccm.2006.11.005","volume":"28","author":"JL Snow","year":"2007","unstructured":"Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med. 2007;28(1):75\u201389. viii.","journal-title":"Clin Chest Med"},{"issue":"3","key":"608_CR16","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/674456","volume":"3","author":"MM Chakinala","year":"2013","unstructured":"Chakinala MM, Barst R. From short-term benefits to long-term outcomes: the evolution of clinical trials in pulmonary arterial hypertension. Pulmonary circulation. 2013;3(3):507\u201322.","journal-title":"Pulmonary circulation"},{"issue":"2","key":"608_CR17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1378\/chest.11-1460","volume":"142","author":"RL Benza","year":"2012","unstructured":"Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL registry. Chest. 2012;142(2):448\u201356.","journal-title":"Chest"},{"issue":"5","key":"608_CR18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","volume":"115","author":"GE D\u2019Alonzo","year":"1991","unstructured":"D\u2019Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991;115(5):343\u20139.","journal-title":"Ann Intern Med"},{"issue":"2","key":"608_CR19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ahj.2009.11.028","volume":"159","author":"A Macchia","year":"2010","unstructured":"Macchia A, Marchioli R, Tognoni G, Scarano M, Marfisi R, Tavazzi L, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010;159(2):245\u201357.","journal-title":"Am Heart J"},{"issue":"3","key":"608_CR20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/CIRCULATIONAHA.112.105890","volume":"126","author":"NB Gabler","year":"2012","unstructured":"Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation. 2012;126(3):349\u201356.","journal-title":"Circulation"},{"issue":"13","key":"608_CR21","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.jacc.2012.01.083","volume":"60","author":"G Savarese","year":"2012","unstructured":"Savarese G, Paolillo S, Costanzo P, D\u2019Amore C, Cecere M, Losco T, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol. 2012;60(13):1192\u2013201.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"608_CR22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.healun.2014.08.020","volume":"34","author":"HW Farber","year":"2015","unstructured":"Farber HW, Miller DP, McGoon MD, Frost AE, Benton WW, Benza RL. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2015;34(3):362\u20138.","journal-title":"The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation"},{"issue":"3","key":"608_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCULATIONAHA.112.118547","volume":"126","author":"HW Farber","year":"2012","unstructured":"Farber HW. Validation of the 6-minute walk in patients with pulmonary arterial hypertension: trying to fit a square PEG into a round hole? Circulation. 2012;126(3):258\u201360.","journal-title":"Circulation"},{"issue":"6","key":"608_CR24","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1378\/chest.09-2060","volume":"137","author":"B Degano","year":"2010","unstructured":"Degano B, Sitbon O, Savale L, Garcia G, O\u2019Callaghan DS, Jais X, et al. Characterization of pulmonary arterial hypertension patients walking more than 450\u00a0m in 6\u00a0min at diagnosis. Chest. 2010;137(6):1297\u2013303.","journal-title":"Chest"},{"issue":"4","key":"608_CR25","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa1209655","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, Galie N, Grimminger F, Grunig E, Humbert M, Jing ZC, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369(4):330\u201340.","journal-title":"N Engl J Med"},{"issue":"4","key":"608_CR26","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","volume":"369","author":"HA Ghofrani","year":"2013","unstructured":"Ghofrani HA, D\u2019Armini AM, Grimminger F, Hoeper MM, Jansa P, Kim NH, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med. 2013;369(4):319\u201329.","journal-title":"N Engl J Med"},{"issue":"5","key":"608_CR27","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/phar.1592","volume":"35","author":"CT Makowski","year":"2015","unstructured":"Makowski CT, Rissmiller RW, Bullington WM. Riociguat: a novel new drug for treatment of pulmonary hypertension. Pharmacotherapy. 2015;35(5):502\u201319.","journal-title":"Pharmacotherapy"},{"issue":"1 Suppl","key":"608_CR28","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.jacc.2009.04.007","volume":"54","author":"VV McLaughlin","year":"2009","unstructured":"McLaughlin VV, Badesch DB, Delcroix M, Fleming TR, Gaine SP, Galie N, et al. End points and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S97\u2013107.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"608_CR29","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1378\/chest.12-3023","volume":"144","author":"AE Frost","year":"2013","unstructured":"Frost AE, Badesch DB, Miller DP, Benza RL, Meltzer LA, McGoon MD. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144(5):1521\u20139.","journal-title":"Chest"},{"issue":"4","key":"608_CR30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.108.809707","volume":"119","author":"C Mehta","year":"2009","unstructured":"Mehta C, Gao P, Bhatt DL, Harrington RA, Skerjanec S, Ware JH. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation. 2009;119(4):597\u2013605.","journal-title":"Circulation"},{"issue":"9","key":"608_CR31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani H-A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369(9):809\u201318. This article is of major importance as it is the first event-driven trial in the field of pulmonary hypertension.","journal-title":"N Engl J Med"},{"key":"608_CR32","doi-asserted-by":"crossref","unstructured":"Preston I. Update on the new landscape and drugs in the pipeline. Advances in pulmonary hypertension. 2014(13:2):76-80.","DOI":"10.21693\/1933-088X-13.2.76"},{"issue":"25 Suppl","key":"608_CR33","doi-asserted-by":"crossref","first-page":"D60","DOI":"10.1016\/j.jacc.2013.10.031","volume":"62","author":"N Galie","year":"2013","unstructured":"Galie N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D60\u201372.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"608_CR34","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Galie","year":"2016","unstructured":"Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67\u2013119. This article is of importance as it summarizes the major PAH treatment recommendations.","journal-title":"Eur Heart J"},{"issue":"2","key":"608_CR35","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.healun.2011.11.002","volume":"31","author":"K Kemp","year":"2012","unstructured":"Kemp K, Savale L, O\u2019Callaghan DS, Ja\u00efs X, Montani D, Humbert M, et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. J Heart Lung Transplant. 2012;31(2):150\u20138.","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"608_CR36","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"73","author":"N Galie","year":"2015","unstructured":"Galie N, Barbera JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;73(9):834\u201344. This article is of major importance because it supports the use of upfront combination therapy for treatment of pulmonary arterial hypertension.","journal-title":"N Engl J Med"},{"key":"608_CR37","doi-asserted-by":"crossref","unstructured":"Nathan SD, Corris PA. Upfront combination therapy: does the AMBITION study herald a new era in the treatment of pulmonary arterial hypertension? Thorax. 2015","DOI":"10.1136\/thoraxjnl-2015-207854"},{"issue":"2","key":"608_CR38","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","volume":"46","author":"V McLaughlin","year":"2015","unstructured":"McLaughlin V, Channick RN, Ghofrani HA, Lemarie JC, Naeije R, Packer M, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J. 2015;46(2):405\u201313.","journal-title":"Eur Respir J"},{"issue":"1","key":"608_CR39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2125.2005.02383.x","volume":"60","author":"GA Paul","year":"2005","unstructured":"Paul GA, Gibbs JSR, Boobis AR, Abbas A, Wilkins MR. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol. 2005;60(1):107\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"608_CR40","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","volume":"45","author":"N Galie","year":"2015","unstructured":"Galie N, Muller K, Scalise AV, Grunig E. PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension. Eur Respir J. 2015;45(5):1314\u201322.","journal-title":"Eur Respir J"},{"issue":"1","key":"608_CR41","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1378\/chest.11-3241","volume":"144","author":"AD Poms","year":"2013","unstructured":"Poms AD, Turner M, Farber HW, Meltzer LA, McGoon MD. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis. Chest. 2013;144(1):169\u201376.","journal-title":"Chest"},{"issue":"6","key":"608_CR42","doi-asserted-by":"crossref","first-page":"794","DOI":"10.4187\/respcare.03927","volume":"60","author":"NS Hill","year":"2015","unstructured":"Hill NS, Preston IR, Roberts KE. Inhaled therapies for pulmonary hypertension. Respir Care. 2015;60(6):794\u2013802. discussion -5.","journal-title":"Respir Care"},{"issue":"6","key":"608_CR43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1378\/chest.11-2212","volume":"142","author":"VF Tapson","year":"2012","unstructured":"Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and\/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest. 2012;142(6):1383\u201390.","journal-title":"Chest"},{"issue":"3","key":"608_CR44","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1378\/chest.12-2875","volume":"144","author":"VF Tapson","year":"2013","unstructured":"Tapson VF, Jing ZC, Xu KF, Pan L, Feldman J, Kiely DG, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Chest. 2013;144(3):952\u20138.","journal-title":"Chest"},{"issue":"5","key":"608_CR45","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.112.124388","volume":"127","author":"ZC Jing","year":"2013","unstructured":"Jing ZC, Parikh K, Pulido T, Jerjes-Sanchez C, White RJ, Allen R, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation. 2013;127(5):624\u201333.","journal-title":"Circulation"},{"issue":"26","key":"608_CR46","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","volume":"373","author":"O Sitbon","year":"2015","unstructured":"Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galie N, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373(26):2522\u201333. This article is of major importance because it is the largest trial to date in the field of pulmonary arterial hypertension.","journal-title":"N Engl J Med"},{"issue":"22","key":"608_CR47","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1161\/CIRCULATIONAHA.114.012328","volume":"132","author":"AB Waxman","year":"2015","unstructured":"Waxman AB, Farber HW. Using clinical trial end points to risk stratify patients with pulmonary arterial hypertension. Circulation. 2015;132(22):2152\u201361.","journal-title":"Circulation"},{"issue":"2","key":"608_CR48","doi-asserted-by":"crossref","first-page":"92","DOI":"10.21693\/1933-088X-13.2.92","volume":"13","author":"SM Studer","year":"2014","unstructured":"Studer SM. Are newer management approaches increasing the economic burden of treating pulmonary arterial hypertension? Advances in Pulmonary Hypertension. 2014;13(2):92\u20133.","journal-title":"Advances in Pulmonary Hypertension"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0608-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-016-0608-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0608-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T01:12:54Z","timestamp":1568250774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-016-0608-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,5]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s11883-016-0608-z","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,5]]},"article-number":"58"}}